However, by overexpressing FMN1 we were not able to sensitize NSCLC cells to cisplatin indicating that either FMN1 is not directly involved in regulating cisplatin sensitivity or it acts in concert with other signaling aberrations to confer survival advantage if down-regulated, which not is recapitulated when forced overexpression is used. This evidence concerns the gene FMN1 and non-small cell lung carcinoma.